Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
IRVINE, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the acceptance of its resubmission of its Biologics License...
-
IRVINE, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced that Health Canada has granted approval of DWP-450...
-
IRVINE, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the appointment of Chief Medical Officer Rui Avelar, MD, as...
-
IRVINE, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) today announced that the underwriters of Evolus’ previously announced public offering that initially closed...
-
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today reported financial results for the second quarter ended June 30, 2018....
-
BLA Resubmission to be Formally Filed Today Commercial Launch Planned for Spring 2019 IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic...
-
IRVINE, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced that it will release 2018 second...
-
IRVINE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today the pricing of its public offering of 4,000,000 shares of common stock at a public offering...
-
IRVINE, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...
-
IRVINE, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the presentation of a...